Building solid partnerships across a variety of expertise plays a significant role in the development of our product pipeline and enables us to better serve people and doctors who need and rely on our treatments.
Since the beginning, HRA Pharma has developed solid relationships with partners over the long term. We enter into these partnerships with integrity, respect, and transparency and with the shared goal of developing innovative, effective, quality treatments and services.
It is our privilege to count among our partners: pharmaceutical companies; public and private institutions; healthcare professionals; the scientific community; and service providers. Moreover, our experienced business development team is constantly look out for new opportunities, and partnerships.
The science of innovation via collaboration
From an internal point of view, HRA Pharma brings to the table clinical expertise and experience in product development, regulatory matters, marketing, market access, and supply chain capabilities. We are adept at launching new brands on a global scale and at understanding the needs of both healthcare professionals and patients.
We are able to leverage our size and set up to adapt to the needs of our partners and we are nimble and adept at doing so. Our wealth of experience and flexibility when structuring deals, for example, has enabled us to maximize the value of our portfolio via in- and out- licensing agreements. We currently market both proprietary and in–licensed products in France and parts of Europe, and out-license our products to marketing partners in other areas of the world. We are able to set-up joint collaborations from co-development programs through co-marketing and co-promotion.
Innovative partnerships and new opportunities
Thanks to our comprehensive business model, we are able to navigate with precision and skill our highly regulated industry and stay one step ahead. We strive to innovate and as such, we are constantly driving forward to identify drugs, devices and biotech products with meaningful clinical benefits. While, our primary focus is on therapeutic categories, such as women's health, reproductive health, consumer health, endocrinology and oncology, we pride ourselves on being flexible in the pursuit of treatments, which is why we are always on the lookout for new opportunities outside of these core, focus areas.
Developing strategic partnerships is a key ingredient for us to achieve our dream of innovating the best medical treatments and making them as accessible as possible.
Forward thinking initiatives – Spotting new opportunities using our insight
SPOT (Strategic Product Opportunity Team)
At HRA Pharma, we have dedicated a full team in-house to searching, screening and securing in-licensing opportunities. Women’s health, endocrinology and oncology and consumer health are the target sectors in which we project to grow both organically and through targeted acquisitions of products or projects that will strengthen and complement our product portfolio.
HRAi™* (*HRA Pharma Incubator)
HRA Pharma is always open to pursuing new opportunities to augment our therapeutic offerings and meet the needs of patients across the world
HRAi™ has been initiated by HRA Pharma to found and support innovative healthcare products and/ or services.
HRAi™ ‘s primary scope of interest is:
• Projects benefitting women’s health.
• Products with a potential OTC (Over-The-Counter) development.
• Innovative projects in niche hospital markets.
HRAi™ may also consider projects in other healthcare areas, provided their innovative potential is sufficient. Projects with short time to market are preferred. Beyond funding, HRAi™ may provide partners with customized support to transform an innovative initiative into a full-fledged global healthcare solution.